Sign in or create an account to add this stock to your watchlist.
About Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400
Debt
Debt-to-Equity RatioN/A
Current Ratio3.93
Quick Ratio3.91
Price-To-Earnings
Trailing P/E Ratio-47.29
Forward P/E Ratio-331.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$165.08 million
Price / Sales5.22
Cash FlowN/A
Price / CashN/A
Book Value$2.92 per share
Price / Book5.67
Profitability
EPS (Most Recent Fiscal Year)($0.35)
Net Income$-15,560,000.00
Net Margins-2.84%
Return on Equity-3.06%
Return on Assets-2.07%
Miscellaneous
Employees273
Outstanding Shares52,110,000
Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions
What is Vanda Pharmaceuticals' stock symbol?
Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."
How were Vanda Pharmaceuticals' earnings last quarter?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported $0.06 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.23. The biopharmaceutical company had revenue of $43.59 million for the quarter, compared to the consensus estimate of $43.30 million. Vanda Pharmaceuticals had a negative return on equity of 3.06% and a negative net margin of 2.84%. The company's revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.11) EPS. View Vanda Pharmaceuticals' Earnings History.
When is Vanda Pharmaceuticals' next earnings date?
What price target have analysts set for VNDA?
5 analysts have issued 12-month target prices for Vanda Pharmaceuticals' stock. Their forecasts range from $18.00 to $27.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $22.40 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.
Who are some of Vanda Pharmaceuticals' key competitors?
Some companies that are related to Vanda Pharmaceuticals include Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX) and ACADIA Pharmaceuticals (ACAD).
Who are Vanda Pharmaceuticals' key executives?
Vanda Pharmaceuticals' management team includes the folowing people:
- Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 58)
- Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 52)
- Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 49)
- Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 52)
- Dr. Deepak Phadke Ph.D., VP of Manufacturing (Age 68)
Has Vanda Pharmaceuticals been receiving favorable news coverage?
Media headlines about VNDA stock have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a news sentiment score of 0.10 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.56 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Vanda Pharmaceuticals' major shareholders?
Vanda Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.19%), venBio Select Advisor LLC (5.33%), Rothschild Asset Management Inc. (2.60%), Millennium Management LLC (1.91%), Prudential Financial Inc. (1.63%) and Northern Trust Corp (1.12%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.
Which institutional investors are selling Vanda Pharmaceuticals stock?
VNDA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., PNC Financial Services Group Inc., Millennium Management LLC, Spark Investment Management LLC, Cortina Asset Management LLC, Schwab Charles Investment Management Inc., JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.
Which institutional investors are buying Vanda Pharmaceuticals stock?
VNDA stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Hawk Ridge Capital Management LP, Alambic Investment Management L.P., Prudential Financial Inc., A.R.T. Advisors LLC, Russell Investments Group Ltd., UBS Group AG and Swiss National Bank. View Insider Buying and Selling for Vanda Pharmaceuticals.
How do I buy shares of Vanda Pharmaceuticals?
Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vanda Pharmaceuticals' stock price today?
One share of VNDA stock can currently be purchased for approximately $16.55.
How big of a company is Vanda Pharmaceuticals?
Vanda Pharmaceuticals has a market capitalization of $885.88 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.
How can I contact Vanda Pharmaceuticals?
Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]
MarketBeat Community Rating for Vanda Pharmaceuticals (VNDA)
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Vanda Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.40, suggesting that the stock has a possible upside of 35.35%. The high price target for VNDA is $27.00 and the low price target for VNDA is $18.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.40 | $22.40 | $22.00 | $22.20 |
| Price Target Upside: | 35.35% upside | 31.61% upside | 38.80% upside | 68.82% upside |
Vanda Pharmaceuticals (NASDAQ:VNDA) Consensus Price Target History
Vanda Pharmaceuticals (NASDAQ:VNDA) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Vanda Pharmaceuticals (NASDAQ:VNDA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.80%
Institutional Ownership Percentage: 90.40%
Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/1/2018 | Gunther Birznieks | SVP | Sell | 8,525 | $18.72 | $159,588.00 | 148,366 |  |
| 3/1/2018 | James Patrick Kelly | CFO | Sell | 8,532 | $18.72 | $159,719.04 | 208,066 | |
| 3/1/2018 | Mihael Hristos Polymeropoulos | Insider | Sell | 60,966 | $18.72 | $1,141,283.52 | 1,243,838 | |
| 1/2/2018 | Gunther Birznieks | SVP | Sell | 8,568 | $15.26 | $130,747.68 | 118,366 | |
| 1/2/2018 | James Patrick Kelly | CFO | Sell | 9,155 | $15.35 | $140,529.25 | 144,721 | |
| 1/2/2018 | Mihael Hristos Polymeropoulos | Insider | Sell | 191,760 | $15.30 | $2,933,928.00 | 1,031,848 | |
| 1/3/2017 | Richard L Gulino | SVP | Sell | 10,900 | $15.51 | $169,059.00 | 12,500 | |
| 9/23/2016 | James E Flynn | Insider | Sell | 1,120,461 | $16.56 | $18,554,834.16 | | |
| 9/19/2016 | James E Flynn | Insider | Sell | 547,886 | $15.66 | $8,579,894.76 | | |
| 1/4/2016 | James Patrick Kelly | CFO | Sell | 9,564 | $8.96 | $85,693.44 | 60,772 | |
| 1/4/2016 | Mihael Hristos Polymeropoulos | CEO | Sell | 21,353 | $8.96 | $191,322.88 | 839,178 | |
| 1/4/2016 | Paolo Baroldi | SVP | Sell | 12,380 | $8.96 | $110,924.80 | 40,665 | |
| 12/11/2015 | James E Flynn | Insider | Buy | 1,201,364 | $8.38 | $10,067,430.32 | | |
| 9/10/2015 | Mihael Hristos Polymeropoulos | CEO | Sell | 131,739 | $12.68 | $1,670,450.52 | 816,781 | |
| 5/22/2015 | Mihael Hristos Polymeropoulos | CEO | Sell | 186,395 | $10.36 | $1,931,052.20 | | |
| 3/9/2015 | Richard W Dugan | Director | Sell | 4,804 | $10.69 | $51,354.76 | | |
| 12/23/2014 | James E Flynn | Insider | Buy | 162,014 | $14.40 | $2,333,001.60 | | |
| 3/14/2014 | Thomas Watkins | Director | Sell | 35,000 | $17.66 | $618,100.00 | | |
| 11/21/2013 | Robert Repella | SVP | Sell | 107,500 | $12.03 | $1,293,225.00 | 15,000 | |
(Data available from 1/1/2013 forward)
Vanda Pharmaceuticals (NASDAQ VNDA) News Headlines
| Source: |
|
Vanda Pharmaceuticals (NASDAQ:VNDA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vanda Pharmaceuticals (NASDAQ:VNDA) Income Statement, Balance Sheet and Cash Flow Statement
Vanda Pharmaceuticals (NASDAQ VNDA) Stock Chart for Monday, May, 21, 2018
Loading chart…
